These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23463394)

  • 1. Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial.
    Chung AY; Ooi LL; Machin D; Tan SB; Goh BK; Wong JS; Chen YM; Li PC; Gandhi M; Thng CH; Yu SW; Tan BS; Lo RH; Htoo AM; Tay KH; Sundram FX; Goh AS; Chew SP; Liau KH; Chow PK; Tay KH; Tan YM; Cheow PC; Ho CK; Soo KC
    World J Surg; 2013 Jun; 37(6):1356-61. PubMed ID: 23463394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis.
    Chua TC; Saxena A; Chu F; Butler SP; Quinn RJ; Glenn D; Morris DL
    Int J Clin Oncol; 2011 Apr; 16(2):125-32. PubMed ID: 21061140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.
    Lau WY; Lai EC; Leung TW; Yu SC
    Ann Surg; 2008 Jan; 247(1):43-8. PubMed ID: 18156922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Intraarterial Lipiodol or ¹³¹I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial.
    Dumortier J; Decullier E; Hilleret MN; Bin-Dorel S; Valette PJ; Boillot O; Partensky C; Letoublon C; Ducerf C; Leroy V; Vuillez JP; Borson-Chazot F
    J Nucl Med; 2014 Jun; 55(6):877-83. PubMed ID: 24722530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis.
    Gong L; Shi L; Sun J; Yuan WS; Chen JF; Liu P; Gong F; Dong JH
    Nucl Med Commun; 2014 May; 35(5):484-92. PubMed ID: 24492679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study.
    Partensky C; Sassolas G; Henry L; Paliard P; Maddern GJ
    Arch Surg; 2000 Nov; 135(11):1298-300. PubMed ID: 11074884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma.
    Furtado R; Crawford M; Sandroussi C
    Ann Surg Oncol; 2014 Aug; 21(8):2700-7. PubMed ID: 24743904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On developing a pragmatic strategy for clinical trials: A case study of hepatocellular carcinoma.
    Gandhi M; Tan SB; Chung Yaw Fui A; Machin D
    Contemp Clin Trials; 2015 Jul; 43():252-9. PubMed ID: 26111924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.
    Lau WY; Leung TW; Ho SK; Chan M; Machin D; Lau J; Chan AT; Yeo W; Mok TS; Yu SC; Leung NW; Johnson PJ
    Lancet; 1999 Mar; 353(9155):797-801. PubMed ID: 10459961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates.
    Keng GH; Sundram FX; Yu SW; Somanesan S; Premaraj J; Oon CJ; Kwok R; Htoo MM
    Ann Acad Med Singap; 2002 May; 31(3):382-6. PubMed ID: 12061301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience.
    Lintia-Gaultier A; Perret C; Ansquer C; Eugène T; Kraeber-Bodéré F; Frampas E
    Nucl Med Commun; 2013 Jul; 34(7):674-81. PubMed ID: 23587835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.
    Boucher E; Corbinais S; Rolland Y; Bourguet P; Guyader D; Boudjema K; Meunier B; Raoul JL
    Hepatology; 2003 Nov; 38(5):1237-41. PubMed ID: 14578862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and prognostic factors after adjuvant
    Olesinski J; Mithieux F; Guillaud O; Hilleret MN; Lombard-Bohas C; Henry L; Boillot O; Walter T; Partensky C; Paliard P; Valette PJ; Vuillez JP; Borson-Chazot F; Scoazec JY; Dumortier J
    Ann Nucl Med; 2017 Jun; 31(5):379-389. PubMed ID: 28342103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study.
    Brans B; De Winter F; Defreyne L; Troisi R; Vanlangenhove P; Van Vlierberghe H; Lambert B; Praet M; de Hemptinne B; Dierckx RA
    Cancer Biother Radiopharm; 2001 Aug; 16(4):333-8. PubMed ID: 11603004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence.
    Nishikawa H; Osaki Y; Kita R; Kimura T; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Sakamoto A; Henmi S; Hatamaru K; Saito S; Nasu A
    Int J Oncol; 2012 Sep; 41(3):903-9. PubMed ID: 22692851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma.
    Kwok PC; Lam TW; Lam PW; Tang KW; Chan SC; Hwang JS; Cheung MT; Tang DL; Chung TK; Chia NH; Wong WK; Chan MK; Lo HY; Lam WM
    J Gastroenterol Hepatol; 2003 Apr; 18(4):450-5. PubMed ID: 12653895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma.
    Schwarz L; Bubenheim M; Gardin I; Huet E; Riachi G; Clavier E; Goria O; Vera P; Scotté M
    World J Surg; 2016 Aug; 40(8):1941-50. PubMed ID: 27098539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma.
    Bhattacharya S; Novell JR; Dusheiko GM; Hilson AJ; Dick R; Hobbs KE
    Cancer; 1995 Dec; 76(11):2202-10. PubMed ID: 8635022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis.
    Tabone M; Vigano' L; Ferrero A; Pellerito R; Carbonatto P; Capussotti L
    Eur J Surg Oncol; 2007 Feb; 33(1):61-6. PubMed ID: 17175128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up.
    Boucher E; Bouguen G; Garin E; Guillygomarch A; Boudjema K; Raoul JL
    J Nucl Med; 2008 Mar; 49(3):362-6. PubMed ID: 18287267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.